News

AbbVie received a positive opinion from the European Medicines Agency's CHMP for Boey for glabellar lines and MAVIRET for acute hepatitis C infection, supporting potential approvals in Europe. The company plans to share new oncology data at the upcoming ASCO Annual Meeting and recently reported strong clinical updates in inflammatory bowel disease therapies. These developments highlight AbbVie's expanding presence in aesthetics, antivirals and immunology alongside upcoming oncology...

Holding a high-yield dividend portfolio in a taxable account at the 24% federal bracket means writing the IRS a $14,400 check every year on $60,000 of income that should have been yours. It repeats annually, forever, on the same dollars you already earned. This series exists because most readers know what a Roth IRA is ... The Dividend Stocks That Generate $60,000 Tax-Free Inside a Roth (And What They Cost You in a Taxable Account)

AbbVie Inc. (NYSE:ABBV) is one of the best low risk stocks to buy in 2026. On May 5, AbbVie presented 18 abstracts at the 2026 Digestive Disease Week Annual Meeting, highlighting new real-world and clinical trial data for its IBD therapies, Skyrizi (risankizumab) and Rinvoq (upadacitinib). The findings demonstrate the long-term efficacy, safety, and durability […]

When investors take a risk-off attitude, stocks with attractive, growing dividends are often their safe-haven option.

The United States market has experienced a flat week but has shown significant growth over the past year with a 27% increase, and earnings are anticipated to grow by 17% annually. In this context, identifying stocks that may be trading below their estimated value can offer opportunities for investors seeking to capitalize on potential future gains.

Replacing a real paycheck with dividends is the cleanest version of financial independence. The income target here is $65,000 per year, roughly the US median individual wage, and the question is whether a $650,000 portfolio can actually produce it. The honest answer up front: only by reaching past pure blue chips into higher-yield categories. Here ... The Dividend Stocks That Can Replace a $65,000 Income and What They’ll Cost You

This big pharma stock checks off a lot of boxes.

In the last week, the United States market has stayed flat, yet it is up 27% over the past year with earnings expected to grow by 17% per annum in the coming years. In this context, identifying stocks that may be undervalued by the market involves looking for companies whose intrinsic value might not be fully reflected in their current share prices despite these positive growth trends.

GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug sales against strong Specialty Medicines growth.

In the last week, the United States market has stayed flat, yet it is up 27% over the past year with earnings forecasted to grow by 17% annually. In such an environment, identifying potentially undervalued stocks like Fifth Third Bancorp can offer investors opportunities for growth at a reasonable price.

The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has built its reputation on paying reliable, growing quarterly distributions to income investors, and the latest data confirms why holders trust the fund. SCHD paid $0.2569 per share on March 30, 2026, continuing an uninterrupted quarterly schedule that stretches back to 2011. For retirees and dividend-growth investors weighing ... Why retirees are banking on SCHD’s 15-year unbroken dividend streak

AbbVie Inc. (NYSE:ABBV) is one of Louis Navellier’s top long-term stock picks. On May 14, Piper Sandler reiterated an Overweight rating on AbbVie (NYSE: ABBV), buoyed by the company’s inflammatory bowel disease (IBD) pipeline. The research firm also raised its price target to $298 from $294, as management moves forward with Skyrizi in combination with […]

Over the last 7 days, the United States market has experienced a slight decline of 1.0%, yet it remains up by an impressive 23% over the past year, with earnings forecasted to grow by 17% annually. In such a fluctuating environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervalued assets.

Regenxbio Inc (NASDAQ:RGNX) is one of the best gene therapy stocks to buy in 2026. On May 14, Regenxbio reported its Q1 2026 financial results and provided operational updates. The company exited the quarter with $150.5 million in cash. The management expects the cash balance to be enough to fund operations into early 2027. Regenxbio […]

Over the last 7 days, the United States market has experienced a slight decline of 1.0%, yet it remains up by an impressive 23% over the past year, with earnings anticipated to grow by 17% annually. In this context, identifying undervalued stocks like Agilysys and others can be an effective strategy for investors seeking opportunities that are priced below their estimated value in a fluctuating market environment.

The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by the President of the United States and quietly outperforming nearly every healthcare benchmark anyway. Trump signed his “most favored nation” drug pricing executive order last May, tying what Medicare pays to lower prices in other ... Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

J&J's expanding pipeline, new drug approvals and rising sales from cancer medicines are expected to fuel growth.

Looking past stocks because they trade at high trailing earnings multiples can be a costly mistake for investors.

AbbVie Inc. (NYSE:ABBV) is included among the Top 12 Undervalued Dividend Stocks to Buy Now. AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. On May 15, Evercore ISI slightly trimmed its price target on AbbVie Inc. (NYSE:ABBV) from $236 […]

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

One is a well-known pharmaceutical company; the other is the king of the medical device segment.

Over the past six months, AbbVie’s shares (currently trading at $211.15) have posted a disappointing 9.8% loss, well below the S&P 500’s 11.5% gain. This might have investors contemplating their next move.

The United States market has remained flat over the last week, yet it has experienced a 24% rise over the past 12 months with earnings forecast to grow by 17% annually. In such an environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors looking to capitalize on anticipated growth.

ABBV's neuroscience sales jump 26% in Q1, driven by Vraylar, migraine drugs and Botox as new therapies fuel growth.

In the last week, the market has stayed flat, yet it is up 24% over the past year with earnings forecasted to grow by 17% annually. In such a vibrant market environment, identifying undervalued stocks can provide investors with opportunities to capitalize on potential growth at a discounted price.

Over the last 7 days, the United States market has risen by 1.1%, and over the past 12 months, it is up by an impressive 27%, with earnings expected to grow by 17% per annum in the coming years. In this context of robust market performance, identifying stocks that are trading below their fair value can be a strategic move for investors seeking opportunities for potential growth and value.

AZN and ABBV both boast strong drug pipelines and growth outlooks, but differences in valuation, dividends and LOE risks set them apart.

ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.

ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales.

Realty Income (NYSE:O) is dominating dividend feeds on Reddit and X again, with monthly-payer loyalists pointing to its 113th consecutive quarterly dividend increase as proof you can collect a check and tune out the rest of the market. The underlying numbers tell a different story. The Math On O Has Quietly Broken O trades at ... Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now